Powerful New Bodyweight Reduction Drug Seeks FDA Approval

If the FDA says yes, a significant new fat loss drug could hit the marketplace this yr. A substantial-dose formulation of liraglutide, the common diabetes drug from Novo Nordisk, melts up to ten % of body mass, studies present.

Liraglutide, available in 1.two mg and one.eight mg doses as Victoza, is already a huge achievement for Novo Nordisk. The firm has now filed with the FDA in search of approval for a 3. mg dose right after studies located key bodyweight loss positive aspects (in conjunction with diet program and exercise.)

In clinical trials, liraglutide helped people taking it drop 5 to ten % of their body mass, according to research published in the Global Journal of Weight problems. And while this study looked at people with diabetes, a preceding examine published in the Lancet examined the drug in non-diabetics and identified similarly impressive weight loss.

In late December, Novo Nordisk filed two submissions for liraglutide, a new drug application (NDA) with the FDA, and a Marketing and advertising Authorization Application (MAA) with the European Medicines Company, according to Drug Discovery &amp Advancement.

But some individuals could not have to wait even that long. In February, Novo Nordisk created the uncommon move of focusing on Mexico for an original approval of large-dose liraglutide. And other folks may not wait at all even though the scientific studies warn towards utilizing liraglutide “off-label” for excess weight loss, it would seem particular that patients will look for to use Victoza for that goal.

Liraglutide works by mimicking a hormone known as GLP-one, which slows digestion and stimulates the body’s natural manufacturing of insulin. Victoza has been extremely profitable for Novo Nordisk, with income jumping 58 percent in 2012, and climbing an further 14 % in the third quarter of 2013.

Experts are projecting that liraglutide would have blockbuster potential as a fat reduction application because the marketplace for excess weight reduction is so large.

The research in non-diabetics, conducted by Arne Astrup of the University of Copenhagen, tested 4 distinct doses of liraglutide: (one.two mg, 1.8 mg, 2.4 mg, and three. mg) towards placebo and another drug, Orlistat and located that folks taking the highest dosage of liraglutide misplaced an common of almost sixteen pounds. Folks taking the reduced doses also lost fat, in between ten pounds with one.2 mg  and 13 pounds at two.four mg.

Just as interesting, liraglutide was located to lower blood sugar in participants who had pre-diabetes, reduced blood sugar, and even aid reduce sleep apnea. The most frequent side effects from liraglutide were mild some participants knowledgeable nausea,vomiting and diarrhea when they first started out taking the drug but in most situations the difficulties subsided more than time.

Nevertheless, there are also a lot more critical safety concerns at present the FDA is investigating the total class of GLP-1 medicines to see if they increase the risk of pancreatitis. Victoza also carries a warning that animal scientific studies found it caused thyroid tumors, both benign and cancerous, in mice, and that it’s “not known” if it could carry the very same risk for people.

And then there’s the truth that liraglutide is administered as an injection, which will most likely demonstrate a barrier for numerous folks, specially offered the availability of oral weight loss medication like Qsymia and Belviq.

Just a few weeks ago the FDA accepted albiglutide (Tanzeum), GlaxoSmithKline’s GLP-1 contender, which only has to be injected when-a-week. One more GLP-one analog drug with equally promising weight reduction likely is Eli Lilly’s dulaglutide, also in the pipeline and also utilised as soon as-a-week. Pharmacists undertaking weight reduction rewards may be just as critical as diabetes management in identifying which GLP-1 drug is most profitable.

AstraZeneca’s Byetta is the other GLP-1 analog on the market Sanofi’s GLP-1 analog Lyxumi launched in Europe in late 2013, but the firm lately withdrew it is application for FDA approval in the U.S. pending an investigation into the drug’s cardiovascular safety.

For much more health information, comply with me right here on Forbes.com, on Twitter, @MelanieHaiken, and subscribe to my posts on Facebook.

Powerful New Bodyweight Reduction Drug Seeks FDA Approval